(ProsperNews.net) – Trump’s revolutionary TrumpRx platform delivers a crushing blow to Big Pharma’s price-gouging schemes while dismantling the corrupt middleman system that has robbed hardworking Americans for decades.
Story Highlights
- TrumpRx.gov slashes GLP-1 drug prices from $1,350 to $350 monthly through direct purchasing
- Federal platform bypasses corrupt PBMs and insurance companies entirely
- Most Favored Nation pricing ensures Americans pay no more than foreign countries
- Five major pharmaceutical companies already signed agreements under tariff pressure
Trump Delivers on Promise to End Prescription Drug Price Gouging
President Trump launched TrumpRx.gov in October 2025, fulfilling his campaign promise to dramatically reduce prescription drug costs for American families. The federal direct-to-consumer platform connects patients directly with pharmaceutical manufacturers at Most Favored Nation prices, matching the lowest prices paid in other developed countries. This revolutionary approach eliminates the corrupt middleman system that has enriched Pharmacy Benefit Managers while bankrupting American patients who desperately need life-saving medications.
The TrumpRx initiative stems from Executive Order 14297 signed May 12, 2025, directing HHS to establish MFN price targets for Medicare and Medicaid programs. Trump sent letters to leading pharmaceutical manufacturers July 31, 2025, outlining requirements to reduce prices to match international levels or face Section 232 tariffs. This aggressive negotiating strategy forced companies to choose between participating in fair pricing or losing access to the lucrative American market through punitive trade measures.
Massive Savings on Critical Obesity and Diabetes Medications
The most dramatic price reductions target GLP-1 drugs used for obesity and diabetes treatment. Novo Nordisk agreed to slash Ozempic prices from $1,000 monthly to $350 through TrumpRx, while Wegovy drops from $1,350 to $350 monthly. Eli Lilly’s Zepbound falls from $1,086 monthly to an average of $346 via the platform. These medications were previously unaffordable for millions of Americans struggling with obesity and diabetes, forcing them to ration doses or go without treatment entirely.
Industry analysis projects TrumpRx GLP-1 prices will trend toward $245 monthly within two years as MFN benchmarks continue driving costs down. Future oral GLP-1 medications for chronic weight management will start at just $150 monthly through the platform, making breakthrough treatments accessible to working-class Americans who have been priced out by corporate greed and insurance company restrictions that prioritize profits over patient health.
Dismantling the Corrupt Healthcare Middleman System
TrumpRx represents a direct assault on the Pharmacy Benefit Manager cartel that has systematically inflated drug costs while skimming billions in rebates and fees. CVS Caremark, Express Scripts, and OptumRx have operated as parasitic middlemen, negotiating secret rebates with manufacturers while forcing patients to pay inflated list prices at the pharmacy counter. The Trump administration’s transparency requirements expose this corrupt system that has enriched corporate executives while denying Americans access to affordable medications.
Five major pharmaceutical companies have already capitulated to Trump’s negotiating pressure, signing MFN agreements that include DTC discounts via TrumpRx and commitments to U.S. manufacturing investments. Pfizer became the first to sign September 30, 2025, followed by AstraZeneca, EMD Serono, Eli Lilly, and Novo Nordisk. These deals demonstrate Trump’s effective use of executive power and trade leverage to force multinational corporations to stop treating American patients as cash cows for subsidizing lower foreign prices.
Mark Cuban’s Cost Plus Drugs partnership with TrumpRx announced October 20, 2025, expands the platform’s reach and operational capacity. This collaboration combines Cuban’s transparent pricing model with federal negotiating power, creating an unstoppable force against pharmaceutical price manipulation. The partnership proves that American entrepreneurs and conservative leadership can work together to solve problems that liberal politicians have ignored for decades while enriching their corporate donors.
Copyright 2025, ProsperNews.net
